Contribution of modeling approaches and virtual populations in transposing the results of clinical trials into real life and in enlightening public health decisions

Therapie

Volumn 67, Issue 4, 2012, Pages 367-374

  Gueyffier, François ^a   Strang, Catherine Brun ^b   Berdeaux, Gilles ^c   França, Lionel Riou ^d   Blin, Patrick ^e   Benichou, Jacques ^f   Massol, Jacques ^d,g  

^a LOUIS PRADEL HOSPITAL   (France)

^b SANOFI   (France)

^c National Conservatory of Arts and Crafts   (France)

^d PhiSquare   (France)

^e Centre of Clinical Investigation Clinical Epidemiology   (France)

^f UNIVERSITÉ DE ROUEN   (France)

^g HÔPITAL SAINT JACQUES   (France)

Author keywords

Clinical trials; Modeling; Public decision; Simulation; Virtual populations

Indexed keywords

DROTRECOGIN;

ALGORITHM; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; CONCEPTION; DECISION MAKING; DRUG RESEARCH; GLAUCOMA; HUMAN; INFORMATION PROCESSING; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MEDICAL RESEARCH; POPULATION MODEL; PRESCRIPTION; PRIORITY JOURNAL; REGISTRATION; REIMBURSEMENT; SEPTIC SHOCK; SIMULATION; PUBLIC HEALTH; RESEARCH;

HUMANS; PUBLIC HEALTH; RESEARCH;

EID: 84869036001     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2012042     Document Type: Article

References (29)

1. http://www.fyma.ucl.ac.be/files/Euler-Bernoulli.pdf
2. Massol J, Zylberman M, Goehrs JM, et al. Use of the foreign studies: transposition of the results, prediction of the therapeutic effects in the french population, modelling of the public health interest. Therapie 2006; 61: 481- 9, 491-9
3. Launay O, Hoch D, Saint-Sardos C, et al. Vaccines: Specific features, simulation of impact and medico-economic modelling. Therapie 2010; 65(4): 357-65
4. Bernard GR, Vincent JL, Laterre PF, et al. The Recombinant Human Activated Protein CWorldwide Evaluation in Severe Sepsis (PROWESS) Study Group, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709
5. Aegerter P, Auvert B, Buonamico G, et al. Organization and quality control of a clinical database on intensive care medicine in central and suburban Paris. Rev Epidemiol Sante Publique 1998; 46(3): 226-37 (Pubitemid 28319736)
6. Riou França L, Launois R, Le Lay K, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care 2006; 22(1): 101-8 (Pubitemid 43376245)
7. Denis P, Lafuma A, Berdeaux G. Medical outcomes of glaucoma therapy from a nation wide representative survey. Clin Drug Investig 2004; 24(6): 343-52 (Pubitemid 38858257)
8. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004; 13(4): 283-90 (Pubitemid 38944196)
9. Nordmann JP, Lafuma A, Deschaseaux C, et al. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. J Glaucoma 2005; 14(6): 463-9 (Pubitemid 41682240)
10. Nordmann JP, Lafuma A, Berdeaux G. Modelling the lifetime economic consequences of glaucoma in France. J Med Econ 2009; 12(1): 9-16
11. Richard JL. The MONICA project. A WHO research project in cardiovascular diseases. Rev Epidemiol Sante Publique 1988; 36(4-5): 325-34 (Pubitemid 19022160)
12. Institut National des Statistiques et d'Etudes Economiques. Structure par âge des populations féminine et masculine. http://www.insee.fr/
13. Marchant I, Boissel JP, Kassai B, et al. SCORE should be preferred to Framingham to predict cardiovascular death in French population. Eur J Cardiovasc Prev Rehabil 2009; 16(5): 609-15
14. Marchant I, Nony P, Cucherat M, et al. The global risk approach should be better applied in french hypertensive patients: a comparison between simulation and observation studies. PLOS One 2011; 6: e17508. doi: 10.1371/ journal.pone.0017508
15. Godet-Thobie H, Vernay M, Noukpoape A, et al. Mean blood pressure level and prevalence of hypertension in 18 to 74 year-old adults, ENNS Survey 2006-2007: InVS; 2008. http://www.invs.sante.fr/beh/2008/49-50/ index.htm
16. Boissel JP, Kahoul R, Amsallem E, et al. Towards personalized medicine: exploring the consequences of the effect model-based approach. Personalized Medicine 2011; 8: 581-6. http://www.futuremedicine.com/doi/abs/10.2217/pme.11.54
17. Marchant I, Gueyffier F. Towards equitable strategies for hypertension management in cardiovascular prevention. Oral communication, EACPT Budapest 2011
18. Caro JJ. Estimation de l'intérêt de santé publique de rimonabant 20mg dans une population française de patients en surpoids ou obèse et diabétiques de type 2 non contrôlés : L'apport d'une modélisation. ALFEDIAM 2007, Marseille, 23 mars 2007
19. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23(4): 323-32 (Pubitemid 40677051)
20. Cooper K, Brailsford SC, Davies R, et al. A review of health care models for coronary heart disease interventions. Health Care Manag Sci 2006; 9(4): 311-24 (Pubitemid 44736856)
21. Caro JJ, Möller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value in Health 2010; 13(8): 1056- 60
22. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72 (Pubitemid 46048528)
23. Boissel JP, Collet JP, Moleur P, et al. Surrogate endpoints, a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-44
24. Gueyffier F, Dib M, Boissel JP. Marqueurs biologiques : biomarqueurs - utilisation au cours du développement et pour l'enregistrement des médicaments. Therapie 2001; 56: 355-61 (Pubitemid 32923872)
25. http://www.ispor.org/workpaper/research-practices/PrinciplesofGood- PracticeforDecisionAnalyticModeling-ModelingStudies.pdf
26. http://www.eisbm.org/include/pdf/eisbm-corporatebrochure.pdf
27. Guide to the Methods of NICE Technolgy Appraisals, NICE, 2008. http:// www.nice.org.uk
28. http://www.eisbm.org
29. http://mastersantepublique.univ-lyon1.fr/, spécialité PHAME (PHArmacologie, Modélisation et Essais Cliniques)